Treatment of peritoneal carcinomatosis with intent to cure

Abstract

After a learning curve of 18 months, the feasibility of the integrated treatment increased to greater than 90%, and mortality dramatically decreased. The combined treatment resulted in a high survival rate in patients with extensive carcinomatosis who were no longer responsive to traditional therapies.

Long-Term Survival of Peritoneal Carcinomatosis of Colorectal Origin

“…Elias et al 9 concluded from their experience in Paris that a 50% 2-year survival could be reached, and the group of Beaujard 22 in Lyon found a median survival of 16 months in patients who underwent successful cytoreduction. The Roman study of Cavaliere et al 23 showed a 2-year survival of 61%. At The Netherlands Cancer Institute, a median survival of 22 months was found in a randomized trial comparing cytoreduction plus HIPEC followed by systemic adjuvant chemotherapy with palliative surgery and systemic chemotherapy.…”

Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: A systematic review and meta-analysis

“…The HIPEC chemotherapy used, temperature and duration was described in all 37 studies (eTable 2). The most commonly used HIPEC chemotherapy was cisplatin (CDDP) that was used either alone [26,42,49,50,55], or in combination with other agents such as doxorubicin [36,37,41,45,56], paclitaxel [40] or mitomycin-C [34,57] Figure 1). Only one study reached median overall survival for CRS with and without HIPEC (64.4 months and 46.4, respectively).…”

Peritoneal Carcinomatosis

“…The first was published by Cavaliere et al [93] reporting about 20 patients with recurrent EOC. They reported a median OS of 25 mo with a 3-year survival of 50%.…”